First randomized trial of a radiopharmaceutical in kidney cancer finds no skeletal benefit
Results of the Alliance for Clinical Trials in Oncology's Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney cancer, found that adding radium-223 to standard care did not improve the length of time patients went without serious bone complications (called skeletal event-free survival) in patients with advanced kidney cancer.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
